<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100858">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01953159</url>
  </required_header>
  <id_info>
    <org_study_id>IRB13-0775</org_study_id>
    <nct_id>NCT01953159</nct_id>
  </id_info>
  <brief_title>Assessment of Paclitaxel-Induced Neuropathy</brief_title>
  <official_title>Validation of a Polygenic Neurotoxicity Risk Score in Patients With Unusually Severe Paclitaxel-Induced Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect clinical data, blood samples, and self reported
      symptoms from patients that experience unusually severe neuropathy after treatment with
      paclitaxel.  This data will be used to develop predictive markers for neuropathy. Blood
      samples will be used to create induced pluripotent stem (iPS) cells and eventually
      artificial nerve cells to be used to study neuropathy in the lab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Validation of polygenic risk score</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be assessed for neuropathy symptoms and predictive markers at the time of enrollment.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cancer,</condition>
  <condition>Breast Cancer,</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with severe neuropathy</arm_group_label>
    <description>Patients with severe neuropathy after treatment with paclitaxel.  Blood samples and patient questionnaires will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without neuropathy</arm_group_label>
    <description>Patients will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age (within 10 years), tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Collection</intervention_name>
    <arm_group_label>Patients with severe neuropathy</arm_group_label>
    <arm_group_label>Patients without neuropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Questionnaires</intervention_name>
    <arm_group_label>Patients with severe neuropathy</arm_group_label>
    <arm_group_label>Patients without neuropathy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, DNA,Peripheral Blood Mononuclear Cells (PBMC)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with paclitaxel
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (Severe Toxicity Group):

          -  Diagnosis of cancer (including, but not limited to, breast and ovarian cancer)

          -  Females aged 18 and older

          -  History of grade 3 or higher peripheral neurotoxicity, any neuromotor, neurocortical,
             or neurocerebellar toxicity, myalgias or arthralgias refractory to non-steroidal
             anti-inflammatory drugs and steroids, ong-term persistence (&gt; 6 months) of grade 2 or
             higher peripheral neuropathy, or other unusually severe neurotoxicity approved for
             inclusion in study by Principal Investigator after completion of paclitaxel
             chemotherapy regimen or history of peripheral neuropathy that required treatment with
             narcotics or grade 2 or higher peripheral neuropathy after only 1 to 2 doses of
             paclitaxel.

        Inclusion Criteria (Control Group):

          -  History of no neurotoxicity (grade 0) after completion of a standard
             paclitaxel-containing chemotherapy regimen

          -  Females age 18 and older

          -  Matched to a specified subject with neurotoxicity based on age (within 10 years),
             tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity

        Exclusion Criteria :

          -  Treatment with other severely neurotoxic chemotherapy (i.e. cisplatin) prior to or
             concomitantly with paclitaxel. Carboplatin therapy is allowed.

          -  Presence of peripheral neuropathy prior to paclitaxel therapy

          -  Poorly controlled or insulin-dependent diabetes or other condition likely to
             predispose to neurotoxicity (alcoholism, Charcot-Marie-Tooth disease)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Koetter, RN</last_name>
      <phone>773-702-1912</phone>
      <email>kkoetter@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Gini Fleming, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>September 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
